From Wikipedia, the free encyclopedia
Jump to: navigation, search
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target NGF
CAS Registry Number 880266-57-9 N
ATC code None
Synonyms RN624
Chemical data
Formula C6464H9942N1706O2026S46
Molecular mass 145.4 kDa
 N (what is this?)  (verify)

Tanezumab (INN, codenamed RN624) is a monoclonal antibody against nerve growth factor. It was developed by Pfizer as a treatment for pain.[1]

In 2009 there was a Phase III trial for knee pain due to osteoarthritis (OA).[2] Another phase III trial for hip pain in OA [3] was halted in June 2010 when some patients needed hip replacement.[4]

Tanezumab is undergoing Phase II clinical trials for the treatment of various pain entities, including chronic low back pain, bone cancer pain, and interstitial cystitis.[5]

In march of 2012 the Anti-NGF Testing - FDA Committee voted in favor of a continuation of the development of nerve-blocking medications, as long as certain safety precautions were observed.

A phase III trial published in 2013 found tanezumab was superior to placebo for painful hip osteoarthritis.[6]


  1. ^ N05, American Medical Association.
  2. ^ "Tanezumab in Osteoarthritis of the Knee".  2009
  3. ^ "Tanezumab in Osteoarthritis Of The Hip". 
  4. ^ http://www.genengnews.com/gen-news-highlights/trials-halted-as-pfizer-s-tanezumab-shown-to-worsen-osteoarthritis/81243572/
  5. ^ "Phase II trials involving Tanezumab". 
  6. ^ "Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial.". Arthritis Rheum. 65: 1795–803. Jul 2013. doi:10.1002/art.37950. PMID 23553790. 

External links[edit]